09/11/2022

Invest in Stenocare, a market leader in medical cannabis.
Import and wholesale of high quality finished medical cannabis products for patients.
Company announcements
Company Introduction
Founded in Denmark in 2017, Stenocare is in the business of supplying medical cannabis products to patients. The company is operating in a highly regulated market under the jurisdiction of local Health Agencies – where the products are only legally available via prescription from a physician to a patient.
Stenocare has its headquarters in Denmark, and a wholly owned subsidiary – Stenocare Ireland Ltd – in Ireland. Stenocare is a Nasdaq listed company and the company shares are traded on Nasdaq First North Growth Market Denmark.

Stenocare vision
Stenocare´s vision is to improve the quality of lives of patients who can benefit from treatment with Medical Cannabis products

Stenocare mission
Stenocare´s mission is to make Stenocare a leading European brand in premium quality prescription-based Medical Cannabis that is following the pharma principles of Good Manufacturing Practice (GMP)

Stenocare strategy
The Stenocare 2.0 strategy is building assets within three categories that supplement each other and are important for the success of the company:
- Commercial assets; having prescription-based medical cannabis products approved in the very strict regulatory regime in Denmark enables the company to leverage this asset in Denmark and future markets. With a multi-supplier approach for sourcing patient-ready products, this is a solid platform for the planned international expansion beyond Denmark.
- Partnership assets; with doctors and patients looking for more product choice for treatment with prescription-based medical cannabis – the company will enter into research and development partnerships to bring exclusive and innovative medical cannabis products to market that differentiate its product portfolio.
- Supply chain assets; where the company controls the entire value chain and builds internal expertise with its own indoor cultivation facility. Having the capability of producing high quality medical cannabis that is controlled and fully documented from seed to sales in the indoor setup that emulates pharma principles is an important asset to be successful in the premium segment that Stenocare is serving in their markets. This will enable it to supply high quality products that meet the requirements of patients, medicines agencies and the pharma industry

These three categories leverage the proven results from the Stenocare 1.0 strategy, that made the company a first-mover in the Danish medical cannabis industry by securing regulatory approvals from The Danish Medicine Agency.
The company has been granted (1) approval to import/manufacture/Distribute medical cannabis products, (2) approval to cultivate and produce medical cannabis products, (3) approval to handle activities with euphoriant substances – and (4) approval to have Stenocare medical cannabis oil and capsule products accepted for the Danish Pilot Programme. The company has cultivated without the use of pesticides in their Danish small scale facility and am in the process of implementing a larger scale indoor state-of-art cultivation facility that build on best practices from greenhouse and clean-room production.
Strong start for 2022 with new products in Denmark and the UK
Stenocare CEO, Thomas Skovlund Schnegelsberg, comments on the important Q1 milestones and key figures in the Q1 Report.

Stenocare initiates guidance: 15-20mDKK in annual revenue run rate by end of 2022
Stenocare has successfully reached two important license milestones during Q1 2022: This enables the company to realize sales to patients in Denmark, Sweden and the UK this year, with a gradual build-up of sales during the year. By the end of the year the expected sales run rate (calculated as Q4 times 4) is set at 15 to 20 million DKK.

Stenocare enters the UK market to sell prescription-based medical cannabis oil products
Stenocare to make medical cannabis oil products available for UK patients. With this Stenocare is taking a major step towards its goal of becoming a European market leader. Stenocare has been working extensively with their partners to establish the logistical setup to cover England, Scotland, Wales and Northern Ireland.

Stenocare approved to supply Danish patients with medical cannabis oil products
Stenocare received approval for a new product from The Danish Medicines Agency, and is again the first and only supplier of medical cannabis oil products for the Pilot Programme. The product is named “THC Olie STENOCARE” and contain 30 mg/mL THC and <0.1 mg/mL CBD, and comes in a 30 mL bottle with an oral syringe.

Healthy Focus On Profitable Business Models
Stenocare CEO Thomas Skovlund Schnegelsberg reflects on 2021 and looks ahead to the challenges and opportunities that lie ahead in 2022.
Click here for full article
Grow-technician is evaluating
The Stenocare grow-technician is evaluating the flower distribution and maturation stage during his inspection. The flower buds are bulking up with plant’s nutrients. The grower is closely monitoring the distribution of the flower buds and leaves for each individual plant. The plants are only few weeks away from harvest, and plant trimming is now concentrated on creating optimal light conditions for all flower buds.
Business perspective for Danish cultivation facility
Stenocare now has capacity to cover its expected supply needs for the next 4-5 years, corresponding to potential annual commercial value of DKK 150 mill from the Danish facility alone. This is not a forecast or guidance for 2022 or 2023, but provide a perspective of the potential capabilities of the Danish facility.

Guided tour in the flower room
Delivering safe prescription-based products to patients require maximum control of quality and documentation.
Guided tour in the water treatment area

Guided tour in the indoor facility area

Good news for the Danish medical cannabis patients and for the industry
Stenocare applauds the Danish Parliament decision to a) extend the Pilot Programme that allow Danish doctors to prescribe medical cannabis and b) to permanently allow local cultivation and production of medical cannabis. This is very good news for patients and the industry.

Prescription: The Danish Parliament today made the decision to extend the Pilot Programme for prescription of medical cannabis with another four years, when the current Pilot expires on 31th of December 2021. This will allow all doctors to continue prescribing medical cannabis products to their patients regardless of illness (ie. indication). The agreement also outlines, that Parliament will debate the levels of patient cost coverage or refund during the Autumn assembly.
Cultivation: The decision today also makes Danish cultivation and production of medical cannabis permanent beyond the expiration of the current Pilot in December 2021. With this decision, Denmark formally continues its ambition to become a leading producer of medical cannabis with an intention to serve both the home market and international markets.
Thomas Skovlund Schnegelsberg, CEO of Stenocare is commenting:
“Today is an important milestone for Danish patients and for the Danish medical cannabis industry. The Danish Parliament has decided to continue the Pilot Programme for patient’s treatment with high quality medical cannabis until 2025, and at the same time made the law for Danish cultivation and production permanent. With this decision, Denmark is now on a path to become a leading producer of medical cannabis for patients in Europa and be an important part of the hyper-growth expected in the coming years.”
Click here for link to The Danish Ministry of Health
Interview Q1 Report 2021
Helge Larsen from Proinvestor.com is interviewing Stenocare CEO about the Q1 2021 Report and state of the business (Danish interview with Swedish subtitles)

Thomas Skovlund Schnegelsberg participated in an interview with Invest Talks published on Dagens Industri (in Swedish)
You can read the full article here – Click here for PDF (PDF doc)
”2020 has both been a exiting and busy year for Stenocare” Stenocare CEO, Thomas Skovlund Schnegelsberg, look back at 2020
“2020 has been a highly extraordinary, yet also busy year for Stenocare. Therefore, I find it natural to share a few reflections as we are nearing the end of 2020. We entered the year with a clear focus upon our Stenocare 2.0 Strategy: to become a European leader within prescription-based medical cannabis”.
Click here for PDF
(PDF doc)
Times Square New York
The iconic “tower photo” from Times Square in New York.
Nasdaq First North Denmark welcomes Stenocare for the first day of trade.


Stenocare and NASDAQ sign the wall poster for the wall of fame
Ceremony of signing the wall poster.
Stenocare´s CEO Thomas Skovlund Schnegelsberg (left) and Carsten Borring (right), Head of Listings, Nasdaq Copenhagen.
Profitable Year-End Report
Join the CEO of Stenocare in his comments on the profitable Year-End Report 2019 and his reflections for the future growth of the company.


Stenocare is a ”company to watch” for 2020
The new edition of The European Cannabis Report 5th Edition was published February 2020, and in the section “Companies to Watch” the Report profile Stenocare as one of few medical cannabis leaders in Europe:
Quote from the Report:
“The company is now a leader in the European market; its production and distribution network in Denmark was profitable in 2018 and is currently expanding to Ireland among other emerging markets. This is notable as even large companies have struggled to produce a profit in the early years of the industry”
The European Cannabis Report is a comprehensive source of information covering each European country and its status/progress with medical cannabis. Therefore the Report offer a good insight into market opportunities, key stakeholders and how medical cannabis is applied for treatment of patients in Europe. The European Cannabis Report is free and is published by Prohibition Partners. Access the Report here.
Stenocare interview
Thomas Skovlund Schnegelsberg, CEO of Stenocare A/S present the Interim Report Second Quarter 2019 and inform about the current challenges relating to Stenocare’s Canadian partner, CannTrust. Annabella Pultz from Finwire is hosting the event.


Stenocare celebrated as the Best IPO 2018 at the ceremony hosted by SvD Börsplus.
The Stenocare Executive Management team, ring the bell at Spotlight Stock Market to start first trade of Stenocare stocks.


Listing ceremony of the first medical cannabis company in Europe.

“Our strategy to become a leading high-end brand in Europe is fueled by the competitive advantage, that we are operating under very strict regulatory control by the medicines agencies”
Marianne Wier
Chairman of the Board
Financial reports
Dates for release of financial information
18/08/2022
19/05/2022
05/05/2022
17/03/2022
24/02/2022
04/11/2021
19/08/2021
20/05/2021
06/05/2021
04/03/2021
25/02/2021
05/11/2020
20/08/2020
14/05/2020
07/05/2020
26/02/2020
06/11/2019
20/08/2019
16/05/2019
07/05/2019
30/04/2019
21/02/2019
21/11/2018
Executive Management

Thomas Skovlund Schnegelsberg, born in 1965, has extensive experience in management, strategy, business development and brand marketing. Read more

Thomas Skovlund Schnegelsberg
CEO and Co-Founder Since 2017Thomas Skovlund Schnegelsberg, born in 1965, has extensive experience in management, strategy, business development and brand marketing. Mr Skovlund Schnegelsberg used to work for Microsoft in Denmark, Nordic, UK and EMEA, where he was employed in senior leadership roles for some 20 years. In addition, Mr Skovlund Schnegelsberg held the professional role of a board member at Lauritz.com where he spent some 11 years. Mr Skovlund Schnegelsberg holds the position of CEO in STENOCARE. Thomas Skovlund Schnegelsberg owns 50 percent of the shares in Prana Holding ApS (a closely related party to Thomas Skovlund Schnegelsberg owns the remaining 50 percent), which owns 1,690,482 in the Company

Søren Kjær, born in 1964, has extensive experience with project management, innovation processes and biotechnology from the horticultural industry. Read more

Søren Kjær
COO, Co-Founder and board member Since 2017Søren Kjær, born in 1964, has extensive experience with project management, innovation processes and biotechnology from the horticultural industry. Past experience includes 20 years of consultancy services at DEVCON and participation in EU projects in Ghana. Mr Kjær holds the position of COO in STENOCARE Søren Kjær owns 50 percent of the shares in MS Kjær Holding ApS (a closely related party to Søren Kjær owns the remaining 50 percent), which owns 1,645,027 in the Company

Rolf Steno Petersen, born in 1965, is a serial entrepreneur and has extensive experience in business innovation, strategy and global sales and marketing. Read more

Rolf Steno Petersen
CCO, Co-Founder and board member Since 2017Rolf Steno Petersen, born in 1965, is a serial entrepreneur and has extensive experience in business innovation, strategy and global sales and marketing. Mr Petersen has been working as CEO at LFP Scandinavia for 14 years and for Techsage (subsidiaries of Esko-graphics BV) for 16 years with sales in 130+ countries, where Mr Petersen was the inventor and partial patent holder. Mr Petersen has held professional roles within the areas of senior management, global support and service and business development. Mr Petersen holds the position of CCO in STENOCARE. Rolf Steno Petersen does not own any shares in STENOCARE. However, Mr Petersen is a senior executive of Steno Group IVS, which owns 1,917,303 in the Company. Steno Group IVS is owned by Jens Thulstrup Steno Petersen, son of Rolf Steno Petersen.

Peter Bugge Johansen, born in 1962, State Authorized Public Accountant. Bugge Johansen worked for 20 years at Interdan Holding A/S, the last six years as CEO and before that as CFO. Read more

Peter Bugge Johansen
CFO Since August 2018Peter Bugge Johansen, born in 1962, State Authorized Public Accountant. Bugge Johansen worked for 20 years at Interdan Holding A/S, the last six years as CEO and before that as CFO. Mr Bugge Johansen has acquired extensive knowledge in financial and strategic issues such as financing, internal and external reporting, change management, group structure, asset management, and mergers and acquisitions. Previous experience includes three years as Tax Manager at A.P. Møller-Mærsk and auditor for 14 years at Deloitte in Denmark and in Italy. Peter Bugge Johansen owns 13,600 shares in the Company, and a 5-year options programme to receive up to 34,000 shares.
Board of Directors

Marianne Wier, born in 1963, holds a law degree from Copenhagen University. Ms Wier has a background as a lawyer and has, through her previous experience, acquired extensive knowledge in leadership and a good strategic understanding. Read more

Marianne Wier
Non-executive Chairman of the Board of Directors Since September 2018Marianne Wier, born in 1963, holds a law degree from Copenhagen University. Ms Wier has a background as a lawyer and has, through her previous experience, acquired extensive knowledge in leadership and a good strategic understanding. Ms Wier’s core skills mainly cover development and innovation as well as change management. Ms Wier has been responsible for implementing a major digital transformation regarding efficiency, digital solutions and innovation at Topdanmark with successful business performance results. In addition, she is a good communicator. Previous experience includes, among other things, COO and Deputy Director of Topdanmark, President and Attorney at Johan Schlüter Law Firm, Group Public Affairs Manager at Danske Bank, and Corporate & Government Affairs Manager at Microsoft Denmark. Marianne Wier is independent of both management and the Company’s major shareholders Marianne Wier owns 11,363 shares in the Company

Søren Melsing Frederiksen, born in 1976, holds a chemical engineering bachelor and a Master of Industrial Drug Development (MIND) from Copenhagen University. Read more

Søren Melsing Frederiksen
Non-executive member of the Board of Directors Since September 2018Søren Melsing Frederiksen, born in 1976, holds a chemical engineering bachelor and a Master of Industrial Drug Development (MIND) from Copenhagen University. Mr Melsing Frederiksen’s experience ranges from R&D, project management, sales management, marketing and product launch, and he has been engaged in all elements of the commercial work, including market access, medical affairs, commercial strategy and sales execution. Mr Melsing Frederiksen currently holds the position as VP Commercial Gx and Promotional Rx at Orifarm A/S Søren Melsing is independent of both management and the Company’s major shareholders Søren Melsing Frederiksen owns 100 percent of the shares in SML Holding ApS, which owns 73,529 shares in the Company

Jeppe Bo Petersen, born in 1966, is currently the CEO of Olivia Danmark A/S, which is one of the largest companies in Denmark’s within personal aid and support schemes. Read more

Jeppe Bo Petersen
Non-executive member of the Board of Directors Since September 2018Jeppe Bo Petersen, born in 1966, is currently the CEO of Olivia Danmark A/S, which is one of the largest companies in Denmark’s within personal aid and support schemes. Mr Petersen has extensive experience within strategic work, operational goals, risk analysis, compliance and sales and marketing. Prior to his contribution at Olivia Danmark A/S, Petersen worked as CFO at, for instance, Valad Europe A/S and Nordicom A/S. In total, Petersen has approximately 30 years of experience within the field of finance. Jeppe Bo Petersen is independent of both management and the Company’s major shareholders Jeppe Bo Petersen owns 1,667 shares in the Company

Søren Kjær, born in 1964, has extensive experience with project management, innovation processes and biotechnology from the horticultural industry. Read more

Søren Kjær
COO, Co-Founder and board member Since 2017Søren Kjær, born in 1964, has extensive experience with project management, innovation processes and biotechnology from the horticultural industry. Past experience includes 20 years of consultancy services at DEVCON and participation in EU projects in Ghana. Mr Kjær holds the position of COO in STENOCARE Søren Kjær owns 50 percent of the shares in MS Kjær Holding ApS (a closely related party to Søren Kjær owns the remaining 50 percent), which owns 1,645,027 in the Company
Please find Articles of Association